Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Home
Researchers
Organisations
Research output
Prizes
Student theses
Courses
Activities
Projects
Press/Media
Datasets
Equipment
Search by expertise, name or affiliation
Renal toxicities associated with pembrolizumab
Hassan Izzedine
, Alexis Mathian
, Stephane Champiat
, Cécile Picard
, Christine Mateus
, Emilie Routier
, Andrea Varga
, David Malka
, Alexandra Leary
, Judith Michels
, Jean Marie Michot
, Aurélien Marabelle
, Olivier Lambotte
, Zahir Amoura
, Jean Charles Soria
, Sihem Kaaki
, Nathalie Quellard
, Jean Michel Goujon
, Isabelle Brocheriou
Ramsay Générale de Santé
Université Paris-Est Créteil
Sorbonne Université
Drug Development Department (DITEP)
Department of Supportive Care
Dermatology Unit
Gastrointestinal Cancer Group
Gynecology Unit
Assistance publique – Hôpitaux de Paris
CHU de Poitiers
Research output
:
Contribution to journal
›
Article
›
peer-review
104
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Renal toxicities associated with pembrolizumab'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Interstitial Nephritis
50%
Acute Kidney Injury
12%
Acute Tubular Injury
37%
Biological Characteristics
12%
Cancer Patients
12%
Cancer Progression
12%
Clinical Experience
12%
Corticosteroid Therapy
12%
Corticosteroids
12%
Dialysis
12%
Duration of Use
12%
Effective Treatment
12%
Glomerular Filtration Rate
12%
Histopathological Features
12%
Kidney Biopsy
12%
Kidney Disease
12%
Kidney Function Recovery
12%
Kidney Involvement
12%
Kidney Pathology
12%
Large Case Series
12%
Minimal Change Disease
37%
Monocentric
12%
Nephrology Referral
12%
Nephropathy
12%
Pembrolizumab
100%
Programmed Death-ligand 1 (PD-L1)
12%
Proteinuria
12%
Referral Center
12%
Reintroduction
12%
Renal Failure
12%
Renal Toxicity
100%
Response to Treatment
12%
Medicine and Dentistry
Acute Kidney Injury
12%
Biopsy
12%
Cancer Growth
12%
Corticosteroid Therapy
12%
Glomerular Filtration Rate
12%
Injury
37%
Interstitial Nephritis
50%
Kidney Dysfunction
12%
Kidney Function
12%
Malignant Neoplasm
12%
Minimal Change Disease
37%
Nephrology
12%
Nephropathy
12%
Nephrotoxicity
100%
Patient Referral
12%
Pembrolizumab
100%
Programmed Cell Death
12%
Proteinuria
12%
Recurrent Disease
12%
Renal Biopsy
12%
Severe Renal Impairment
12%